Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluation of an Improved Reactive Mercury Active System: Uncertainties and Applicability in Polluted Environments.

Environmental science & technology·2026
Same author

A Versatile Multiplexed Immunofluorescence Strategy for Efficient, Host-Independent, and Scalable Spatial Protein Profiling.

Small methods·2026
Same author

Vacuum-assisted excision versus open surgery for intraductal lesions: a systematic review and meta-analysis of therapeutic effectiveness, safety, and patient-reported outcomes.

Gland surgery·2026
Same author

Evaluating adverse reaction signals of vancomycin in pediatric patients: A FAERS database analysis.

Medicine·2026
Same author

Enhanced photoreduction of perfluorooctane sulfonate via a confined nitrilotriacetic acid system augmented by CTAB.

Journal of hazardous materials·2026
Same author

Engineering of Lewis Acid Sites in Mesoporous Zeolite Achieves Record Fructose Yield of 71.5% for Glucose Isomerization in Ethanol.

Angewandte Chemie (International ed. in English)·2026

相关实验视频

Updated: Sep 10, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.2K

针对miR-325-3p/ GSTP1轴通过诱导铁死来克服三阴性乳腺癌中的帕克利塔塞尔耐药性.

Huiling Wang1, Feng Yang2, Yaqin Wu1

  • 1Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), NO 89, Guhan Road, Changsha, 410006, Hunan, China.

Genes & genomics
|August 20, 2025
PubMed
概括
此摘要是机器生成的。

在三阴性乳腺癌 (TNBC) 中克服帕克利塔塞尔耐药性需要向miR-325-3p/ GSTP1通路. 恢复miR-325-3p会诱导铁和亡,使TNBC对化疗敏感.

关键词:
铁症一个GSTP1对帕克利塔克塞尔的耐药性三重阴性乳腺癌 (TNBC)miR-325-3p 的使用情况

更多相关视频

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

相关实验视频

Last Updated: Sep 10, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.2K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

科学领域:

  • 癌症学
  • 分子生物学
  • 生物化学

背景情况:

  • 三重阴性乳腺癌 (TNBC) 具有有限的治疗选择,帕克利塔塞尔耐药性是一个重要的临床障碍.
  • 铁,一种依赖于铁的细胞死亡,以及像miR-325-3p这样的微RNA (miRNAs),都与化学抵抗有关,但它们在TNBC中的作用尚不清楚.

研究的目的:

  • 调查铁和miR-325-3p在TNBC中对帕克利塔塞尔耐药性的作用.
  • 阐明 miR-325-3p 对化学阻力的影响的分子机制.

主要方法:

  • 建立了抗帕克利塔塞尔的TNBC细胞系,并用铁灭调节剂治疗它们.
  • 在耐药和敏感的TNBC组织和细胞中评估miR-325-3p表达.
  • 使用功能性测试来评估细胞活力,细胞亡和铁亡标记,并验证GSTP1作为直接的miR-325-3p目标.

主要成果:

  • 铁死诱导剂对抗性TNBC细胞产生敏感性,而抑制剂则降低了这种作用.
  • 它的过度表达促进了亡和铁亡,恢复了帕克利塔塞尔的敏感性.
  • GSTP1被确定为直接目标,其恢复部分逆转了miR-325-3p的影响,表明miR-325-3p/ GSTP1轴调节了耐药性.

结论:

  • 这一 miR-325-3p/ GSTP1 轴是通过铁变异调节来调节 TNBC 中的帕克利塔塞尔耐药性的关键调节器.
  • 针对miR-325-3p/ GSTP1通路提供了一种潜在的治疗策略,以克服TNBC的化学抵抗.